drugset / Trial / NCT06482034

Effect of N-acetyl Cysteine and Zinc in Management of Head and Neck Cancer Radiotherapy Induced Oral Mucositis

NCT06482034

Phase 2 Completed 50 enrolled Mansoura University
RandomizedParallel-groupDouble-blindPrevention

Summary

The majority of individuals diagnosed with head and neck cancer, who undergo radiotherapy or concurrent Chemoradiotherapy, experience oral mucositis. Our research focuses on investigating the preventive and therapeutic impact of N-acetylcysteine and zinc in managing radiotherapy-induced oral mucositis.

Timeline

Start
2023-06-28
Primary completion
2024-09-30
Completion
2024-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject N-acetylcysteine Small molecule 600 mg Oral
Subject Zinc Sulfate Unknown 25 mg Oral

Indications